Please use this identifier to cite or link to this item:
Title: The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis”
Author: Sampayo Cordero, Miguel
Miguel Huguet, Bernat
Malfettone, Andrea
Pérez García, José Manuel
Llombart Cussac, Antonio
Cortés, Javier
Pardo, Almudena
Pérez López, Jordi
Keywords: Malalties rares
Assaigs clínics
Rare diseases
Clinical trials
Issue Date: 22-Jun-2021
Publisher: Frontiers Media SA
Abstract: Nonrandomized studies are usually excluded from systematic reviews. This could lead to loss of a considerable amount of information on rare diseases. In this article, we explore the impact of excluding nonrandomized studies on the generalizability of meta-analyses results on mucopolysaccharidosis (MPS) disease. A comprehensive search of systematic reviews on MPS patients up to May 2020 was carried out (CRD42020191217). The primary endpoint was the rate of patients excluded from systematic reviews if only randomized studies were considered. Secondary outcomes included the differences in patient and study characteristics between randomized and nonrandomized studies, the methods used to combine data from studies with different designs, and the number of patients excluded from systematic reviews if case reports were not considered. More than 50% of the patients analyzed have been recruited in nonrandomized studies. Patient characteristics, duration of follow-up, and the clinical outcomes evaluated differ between the randomized and nonrandomized studies. There are feasible strategies to combine the data from different randomized and nonrandomized designs. The analyses suggest the relevance of including case reports in the systematic reviews, since the smaller the number of patients in the reference population, the larger the selection bias associated to excluding case reports. Our results recommend including nonrandomized studies in the systematic reviews of MPS to increase the representativeness of the results and to avoid a selection bias. The recommendations obtained from this study should be considered when conducting systematic reviews on rare diseases.
Note: Reproducció del document publicat a:
It is part of: Frontiers in Molecular Biosciences, 2021, vol. 8 num. 690615
Related resource:
ISSN: 2296-889X
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
fmolb-08-690615.pdf1.06 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons